Boston Scientific added SNM to its urology portfolio following its 2024 acquisition of Axonics.

Among the highest performers were multiple facilities in Nashville, Middle Tennessee and surrounding communities.

Dyslipidemia should be treated earlier to reduce lifelong risk for prolonged exposure to atherogenic lipoproteins.

Outside, a snowstorm is gathering strength. Winds are rising to thirty miles per hour, and two feet of snow are expected over the next two days. Around the dinner table in my home, an unexpected topic ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal and rare cancer session and a Society of Urologic Oncology (SUO) lecture ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Since joining Driscoll in 2024, he has expanded pediatric urology offerings, including new technologies that enable faster ...

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research.

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...